Adjunct acne, dermatoses treatments offer high potency, low risk

February 19, 2005

PharmaDerm is launching two new marketing campaigns toward dermatologists at the 63rd Annual Meeting.

Malcolm McCoy, vice president, sales and marketing (right) talks with sales representatives at the PharmaDerm exhibit.

PharmaDerm is launching two new marketing campaigns toward dermatologists at the 63rd Annual Meeting.

PharmaDerm's newest product, ApexiCon E Cream (diflorasone diacetate cream USP, 0.05 percent [emollient]) is a high potency steroid therapy with a low risk of adverse side effects, according to Malcolm McCoy, vice president, sales and marketing.

It is a topical treatment for corticosteroid-responsive dermatoses, including eczema, psoriasis and contact dermatitis.

PharmaDerm's ClindaMax Lotion (clindamycin phosphate topical suspension USP, 1 percent) is an anti-inflammatory acne treatment effective for all skin types with low risk of adverse side effects. It has been shown to be effective when used alone or as an adjunct to other topical medications, including retinoids, Mr. McCoy says.

Visit PharmaDerm at booth 3657.